Liying "Lily" Zhang

Dr. Liying "Lily" Zhang


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
LZLiying "Lily" Zhang
Liying "Lily" Zhang
SASaleh Altuwaijri
Saleh Altuwaijri
FDFangming Deng
Fangming Deng
LCLishi Chen
Lishi Chen
PLPriti Lal
Priti Lal
WGWilliam L. Gerald
William L. Gerald


10 December 2020 in Human Mutation
Verified
Journal Article
Closed access
PDF file
CFCristina Fortuno
Cristina Fortuno
KLKristy Lee
Kristy Lee
MOMagali Olivier
Magali Olivier
TPTina Pesaran
Tina Pesaran
PMPhuong L. Mai
Phuong L. Mai
TPthe ClinGen TP53 Variant Curation Expert Panel
the ClinGen TP53 Variant Curation Expert Panel

15 February 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
EFElise M. Fiala
Elise M. Fiala
GJGowtham Jayakumaran
Gowtham Jayakumaran
AMAudrey Mauguen
Audrey Mauguen
JKJennifer A. Kennedy
Jennifer A. Kennedy
NBNancy Bouvier
Nancy Bouvier
MWMichael F. Walsh
Michael F. Walsh

16 October 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
XLXi Luo
Xi Luo
SFSimone Feurstein
Simone Feurstein
SMShruthi Mohan
Shruthi Mohan
CPChristopher C. Porter
Christopher C. Porter
SJSarah A. Jackson
Sarah A. Jackson
LGLucy Godley
Lucy Godley
Standardized variant curation is essential for clinical care recommendations for patients with inherited disorders. Clinical Genome Resource (ClinGen) variant curation expert panels are developing disease-associated gene specifications using the 2015 American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines to reduce curation discrepancies. The ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) was created collaboratively between the American Society of Hematology and ClinGen to perform gene- and disease-specific modifications for inherited myeloid malignancies. The MM-VCEP began optimizing ACMG/AMP rules for RUNX1 because many germline variants have been described in patients with familial platelet disorder with a predisposition to acute myeloid leukemia, characterized by thrombocytopenia, platelet functional/ultrastructural defects, and a predisposition to hematologic malignancies. The 28 ACMG/AMP codes were tailored for RUNX1 variants by modifying gene/disease specifications, incorporating strength adjustments of existing rules, or both. Key specifications included calculation of minor allele frequency thresholds, formulating a semi-quantitative approach to counting multiple independent variant occurrences, identifying functional domains and mutational hotspots, establishing functional assay thresholds, and characterizing phenotype-specific guidelines. Preliminary rules were tested by using a pilot set of 52 variants; among these, 50 were previously classified as benign/likely benign, pathogenic/likely pathogenic, variant of unknown significance (VUS), or conflicting interpretations (CONF) in ClinVar. The application of RUNX1-specific criteria resulted in a reduction in CONF and VUS variants by 33%, emphasizing the benefit of gene-specific criteria and sharing internal laboratory data.

15 March 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ECEmiliano Cocco
Emiliano Cocco
JBJamal Benhamida
Jamal Benhamida
SMSumit Middha
Sumit Middha
AZAhmet Zehir
Ahmet Zehir
KMKerry Mullaney
Kerry Mullaney
JHJaclyn F. Hechtman
Jaclyn F. Hechtman
Kinase fusions are rare and poorly characterized in colorectal carcinoma, yet they present unique opportunities for targeted therapy. In this study, we characterized kinase fusions from patients with advanced colorectal carcinoma who had MSK-IMPACT testing of their tumors between January 2014 and June 2018. Patients were analyzed for the presence of fusions, microsatellite instability (MSI), and RAS/BRAF mutations. Mismatch repair (MMR), IHC, and promoter hypermethylation status of MLH1 (MLH1ph) in microsatellite instability-high (MSI-H) colorectal carcinoma with fusions were investigated. Fusion transcripts were confirmed using a targeted RNA-seq panel assay. Of 2,314 colorectal carcinomas with MSK-IMPACT testing, 21 harbored kinase fusions. Overall 57% (12/21) of colorectal carcinoma fusions were MSI-H/MMR-D. Loss of MLH1 and MLH1ph was confirmed in all 12 and all 10 cases with available material, respectively. Fusions were present in 5% of MSI-H/MMR-D colorectal carcinoma compared with 0.4% of MSS/MMR-P colorectal carcinoma (P < 0.001) and 15% of MSI-H/MMR-D colorectal carcinoma with wild-type RAS/BRAF. Of 24 total MLH1-deficient colorectal carcinomas with MLH1ph and wild-type RAS/BRAF, 10 (42%) harbored kinase fusions. Kinase fusions in MSI-H colorectal carcinoma were associated with sporadic MLH1ph rather than with Lynch syndrome, and these patients may be eligible for kinase inhibitors, particularly following resistance or toxicity in response to immunotherapy. These findings identify a molecular subset of colorectal carcinoma with kinase fusions that may be responsive to kinase inhibitors. Significance: A high frequency of targetable kinase fusions in BRAF/RAS wild-type, MSI-H colorectal carcinoma offers a rationale for routine screening to identify patients with colorectal carcinoma with kinase fusions that may be responsive to kinase inhibitors. See related commentary by Valeri, p. 1041